Tokyo, July 27 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062323) titled 'A Prospective Study of Early Intervention and Risk Factors for Hyperglycemic Adverse Events in Patients Receiving Capivasertib' on July 27.
Study Type:
Interventional
Study Design:
Basic Design - Single arm
Randomization - Non-randomized
Blinding - Open -no one is blinded
Control - Uncontrolled
Primary Sponsor:
Institute - Osaka Red Cross Hospital
Condition:
Condition - Unresectable or recurrent hormone receptor-positive, HER2-negative breast cancer with PIK3CA/AKT1/PTEN gene mutations that progressed after endocrine therapy
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative ...